Happy Holidays from all of us at ICON. We’re sending every best wish for health, happiness and success in 2026.
In the News
ICON experts frequently author or contribute to industry trade press.
Filter media
Filter media articles by either clicking within the ‘Category’ drop-down list, or begin typing which will automatically match to the nearest available category. Note - not all categories will display results if selecting a particular year.
-
48% of biotechs leaning on Big Pharma as current funding method: ICON survey
This article from Fierce Biotech provides an overview of findings from the ICON 2023 biotech sector survey, which shows that despite cash struggles, 60% of the survey respondents anticipate their R&D spend to rise over the next one to two years.
-
Due diligence and beyond
Dr. Sandra Eagle outlines how due diligence has evolved from a discrete standalone technical assessment, to now being an integrated part of the holistic development continuum of an asset.
-
Optimising biotech trial designs to stretch your cash runway
Brandon Early discusses how optimising trials designs at the earliest stages can help innovative biotech companies to maximise their available capital.
-
-
What Biotech and Pharma need to consider about decentralised trials
Discuss key considerations when implementing decentralised clinical trials, in addition to the success factors that lead to more patient-centric trials and increased patient recruitment, engagement and retention.
-
So what sectors had the most M&A activity?
This article shares how the medical and biotech sectors have dominated the mergers & acquisitions (M&A) landscape and mentions ICON’s acquisition of PRA Health Sciences. (registration required)
-
How CRO venture capital relationships can help biotech fundraising
This article considers how partnering with a CRO can help emerging biotechs to secure funding.
-
R&D outsourcing trends roundtable
Solomon Babani, SVP and General Partner, Biotech and Small/Mid-Size Pharma, contributes to this article on today’s R&D outsourcing trends across drug development, clinical trial services and manufacturing.
-
Europe’s emerging biotechs: Challenges, opportunities and funding
John Macdonald, Vice President, Venture & Financial Alliances, examines the European biotech sector – its expertise and opportunities, and potential for growth.
-
Best practices in managing CGT from protocol design to data management
Though the fields of immunotherapy and cell and gene therapies have seen significant growth since April 2012, CGT clinical research remains a challenge. ICON's Tamie Joeckel offers expert commentary on managing and executing CGT clinical trials.
